ABSTRACT
Score) or other immunohistochemistry or gene expression profiles might suggest malignancy but are still not diagnostic. [8] [9] [10] The distant metastases are usually of hematologic origin, mostly involving bone, liver and lung. Since metastasis represents the only accepted criterion for malignancy, it is important to distinguish between metastasis and multifocality which may occur, especially in inherited disorders. [11] [12] [13] heredItary pheochroMocytoMa
Up to 25% of pheochromocytoma cases are hereditary. 11, 14 It is to be noted that the first described case of pheochromocytoma (1886) was recently proven to be a patient with MEN2. 15, 16 Six pheochromocytoma-associated syndromes have thus far been identified. The first to be described was neurofibromatosis type 1 syndrome (NF1) reported by Suzuki et al in 1910 . 17 The most famous are the multiple endocrine neoplasia type 2 (MEN2) and von Hippel-Lindau Syndrome (VHL). 18 Recently, three new syndromes associated with pheochromocytoma have been identified: PGL syndrome types 1, 3 and 4, 13, [19] [20] [21] all following an autosomal dominant inheritance pattern. For PGL 1, maternal imprinting of the susceptibility gene has been proposed, thus implying that only a carrier inheriting the mutation from the father will develop the disease; an exception to this rule has been observed, but the case is unclear. 22, 23 The presence of several reports of familial non-syndromic cases indicates that the prevalance of inherited cases might be higher than currently recorded. 24, 25 A summary of pheochromocytoma presentation in the different syndromes is represented in Table 1 .
Neurofibromatosis type 1
The susceptibility gene, NF1, located on the long arm of chromosome 17 (17q11.2) with 57 coding exons, is the largest pheochromocytoma susceptibilty gene described so far. 26 The diagnosis is clinical and is based on the presence of café-au-lait spots, fibromatous tumours of the skin, axillary freckling and Lisch nodules of the iris. About 1-3% of patients with NF1 develop a pheochromocytoma. 27 The mean age of pheochromocytoma onset is 42 years; 84-95% of patients have solitary adrenal tumours, 5-10% have
IntroductIon
Paragangliomas (PGL) are tumours of the paraganglia, a collection of neuroendocrine tissues and small organs with a common neuroectodermal origin and histological structure. Paraganglia may be either part of the sympathetic or the parasympathetic vegetative nervous system. Sympathetic paraganglial tissue (chromaffin) is mainly located in the adrenal medulla, but also in prevertebral and paravertebral thoraco-abdominal and pelvic paraganglia or ganglia in ovary, testis, vagina, urethra, prostate, bladder or liver and the Zuckerkandl organ. The parasympathetic paraganglia (non-chromaffin) are usually located in the vicinity of major arteries and nerves: the most common is the carotid body tumour, followed by jugular, vagal, tympanic, pulmonary and aortic paragangliomas. 1, 2 We prefer to use the term pheochromocytoma for both adrenal and sympathetic paraganglia (chromaffin) derived extra-adrenal tumours, which are usually endocrinologically active. We describe as paraganglioma those tumours arising from parasympathetic paraganglia (non-chromaffin) located in the skullbase and neck region which are usually hormonally inactive. 3 The terminology is not uniform, the World Health Organization (WHO) Tumour Classification defining as pheochromocytoma only chromaffin tumours arising from the adrenal medulla, while all other tumours (chromaffin and non-chromaffin origin) being classified as extra-adrenal paragangliomas. 4 In this work a clinical view of pheochromocytoma with particular reference to the hereditary forms is presented.
pheochroMocytoMa epIdeMIology
Pheochromocytoma is a rare tumour with an approximate incidence of 2-8 cases per million per year, with the highest incidence occurring between 50-60 years, without gender difference. 5 It is responsible for 0.2-0.4% of cases of arterial hypertension. 5 The malignancy rate is variable, from 2.4-26%. 6, 7 There are no histological proofs of malignancy to date and the only accepted criterion is the presence of metastasis. Histological indices, such as the Thompson PASS (Pheochromocytoma of the Adrenal Gland Scaled bilateral adrenal disease and 0-6% have extra-adrenal pheochromocytomas; malignant pheochromocytomas are present in 3-12% of the cases. 28, 29 There is no correlation between the mutation type and the pheochromocytoma behaviour.
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Multiple endocrine neoplasia type 2
Two subtypes of this syndrome are associated with pheochromocytoma, MEN2A and 2B.
MEN2 is characterized by Medullary Thyroid Carcinoma (MTC) present in >90% of cases; in the MEN2A 20% of cases are diagnosed with primary hyperparathyroidism, whilst MEN2B is characterized by ganglioneuromas of the mucosa and marfanoid habitus.
Activating mutations of the RET proto-oncogene are involved in the pheochromocytoma genesis. The RET gene lies on the long arm of chromosome 10 (10q11.2) and consists of 16 exons, of which exons 10, 11, 13 and 16 are mainly associated with pheochromocytoma. About 50% of MEN2A and 2B cases develop a pheochromocytoma, but the overall and age-related penetrance varies between different mutations. 30, 31 The pheochromocytoma is usually adrenal, frequently bilateral and rarely extra-adrenal or malignant.
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Von Hippel-Lindau Syndrome
We distinguish two major subgroups of VHL Syndrome: VHL type 1 mainly without and VHL type 2 mainly with pheochromocytoma presentation. 32 The clinical features of the VHL syndrome include retinal (von Hippel) and cerebellar (Lindau) hemangioblastoma, as well as brainstem and spinal hemangioblastoma. They also include presence of renal cysts and renal cell carcinoma, pancreatic cysts and islet cell tumours, endolymphatic sac tumours, as well as cysts and cystadenomas of epididymis and broad ligament ( Figure 1 ).
The VHL gene lies on the short arm of chromo- frequently pheochromocytomas, single and extraadrenal, with a higher percentage of malignant cases (up to 34%). For both syndromes the age at onset of tumour manifestations was earlier compared with the sporadic forms. 12, 39 Paraganglioma syndrome type 3 was initially associated with only head and neck paragangliomas, with no difference in age at onset as compared to the sporadic cases, and were mostly benign. 40, 41 Recently, two cases presenting with benign adrenal and extra-adrenal pheochromocytoma were described. Larger series are necessary for better definition of pheochromocytoma presentation within this syndrome. 13, 21 Other tumours that have been associated with paraganglioma syndromes are renal clear cell carcinoma (RCC) and Gastrointestinal Stromal Tumours (GIST). Whilst RCC is associated with mutations in the SDHB gene, mutation in all three genes have been identified in patients with the Carney-Stratakis dyad of paraganglioma and gastric stromal tumour.
42,43 syMptoMs and sIgns
There is a long list of pheochromocytoma-associated symptoms and signs (Table 2 ) and they are all related to excessive catecholamine (epinephrine, norepinephrine and dopamine) excretion. The classical triad of palpitation, headache and excess sweatiness are present in only 15-24% of cases. [44] [45] [46] In half of the patients, hypertension is present as a constant feature, whilst it is intermittent in the remaining half. Normal blood pressure is rare in pheochromocytoma patients, even though new studies have shown a lower prevalence (60-70%) of hypertension, especially in dopamine-secreting tumours. [44] [45] [46] [47] The symptoms of pheochromocytomas are usually intermittent due to the intermittent catecholamine excess. In 75% of cases the symptoms occur weekly, while in others this can be daily or at intervals of several months. Crisis due to untreated catecholamine excess can lead to heart insufficiency, pulmonary oedema, respiratory distress, heart arrhythmias, intracerebral bleeding and death.
Signs and symptoms of malignant pheochromocytoma are related to the infiltration of the tumours into both neighbourhood structures and distant organs. 48 some 3 (3p25), with 3 exons coding for 2 isoforms of the protein. 33 The mutations are spread in all three exons. Missense mutations, usually confer better prognosis and are more frequently detected in patients presenting with pheochromocytoma. 34 About 20-30% of VHL type 2 patients develop a pheochromocytoma. The age at diagnosis is younger than in sporadic cases. They are frequently multiple: bilateral adrenal and multifocal extra-adrenal. Rarely, they are malignant.
Paraganglioma Syndromes
Three of the four described Paraganglioma Syndromes (PGL), Types 1, 3 and 4, are associated with pheochromocytoma. The susceptibility genes SDHB (PGL 4), SDHC (PGL 3) and SDHD (PGL 1) code the three subunits of the succinate dehydrogenase enzyme, 35 while the fourth subunit coded by the SDHA gene is not associated with hereditary paraganglioma. 36 Paraganglioma syndrome type 2, for which the susceptibility gene has not as yet been identified, has been diagnosed in families with head and neck paraganglioma, but not pheochromocytoma. 37 Patients with SDHD gene (PGL 1) defect mainly develop head and neck paraganglioma rather than pheochromocytomas. The pheochromocytomas are usually benign and multifocal. One case with PGL 1 is represented in Figure 2 . 38 In contrast, patients with SDHB gene mutations (PGL 4) develop more Asymptomatic pheochromocytoma is rare and it is mainly detected in mutation carriers after clinical screening. In these cases, retrospective analysis of symptoms and signs of the tumour manifestation suggests an asymptomatic or mildly symptomatic state.
dIagnosIs of pheochroMocytoMa
The diagnosis is based on biochemical testing and imaging. Biochemical testing alone is insufficient, especially in screening for tumours in patients at risk (mutation carriers).
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Biochemical Diagnosis
Excess of catecholamines (epinephrine, norepinephrine, dopamine) and their metabolites in the plasma or urine are the basis of biochemical testing. Due to intermittent catecholamine secretion, serial measurements might show different values. In the majority of symptomatic cases the catecholamine excess is also present in asymptomatic phases.
The most commonly applied tests include measurements of plasma and urinary epinephrine and norepinephrin, as well as the urinary vanillylmandelic acid (VMA) and the plasma free or urinary (fractioned or total) metanephrine and normetanephrine. Several methods have been used for this determination, including spectrophotometry, high pressure liquid chromatography (HPLC) and radioimmunoassays. The most sensitive method is the determination of plasma free metanephrines. 51 The HPLC-Method used for the latter is available in only a limited number of medical centres, and thus the determination of plasma and urinary catecholamines and total urinary metanephrines are common practice. For urinary assays it might be important to concomitantly determine the creatinine clearance to detect eventual collection errors.
Usually at least a 2-to 3-fold level elevation of the assay's given normal range is present in pheochromocytoma patients. False positive results may be present due to stress or concomitant use of drugs (acetaminophen, tricyclic antidepressants, phenoxybenzamine, L-DOPA, high-dose diuretics) or dietary products (caffein, nicotine) which might influence some of the assays or act on the physiology of catecholamines excretion. 48 In screening of at risk patients (with known inherited disorder), the false negative results are much higher compared to the sporadic cases. 51 One of the reasons could be the tumour size, being much smaller in routinely screened, at risk patients compared to symptomatic cases. 52 Differences in the secretion patterns have been observed in the various localizations of the tumour as well between the tumours associated with different hereditary syndromes. 52 Extra-adrenal pheochromocytomas as well as tumours associated with VHL syndrome, are mostly noradrenergic. Pheochromocytoma associated with MEN2 manifest more frequently an adrenergic pattern.
Radiological Imaging
Computer tomography (CT) and Magnetic Resonance Imaging (MRI) represent the methods of choice for cross-sectional imaging of pheochromocytoma.
Using these methods, tumour of sizes 0.5 to 1 cm can be detected. Comparing the two methods, CT has the advantage of lower costs, but MRI has a slightly higher sensitivity and a lack of exposure to ionizing radiation, which is an important factor in hereditary cases undergoing continuous clinical follow-up. 53 Since small extra-adrenal primary or metastatic tumours might be missed, anatomical imaging studies should be combined with functional (nuclear medicine) imaging studies for optimal results. The latter have a special role in localization of tumours in inherited disorders. They also give an idea of the endocrinological activity of the tumours, which can be useful in the further management (see below).
The three approaches include:
123 I-MIBG Scinitgraphy, 18 F-DOPA or 18 F-DOPAMINE, positron emission tomography (PET) and 111 In-octreotide scintigraphy (OCTREOSCAN). 53 The radioactive tracer used in these approaches has an almost exclusively paraganglial tissue uptake. 54, 55 The most frequently used is 123 I-MIBG-scintigraphy, widely available and highly specific (95-100%) but with a sensitivity of 77-90%.The uptake of 123 I by the thyroid should be blocked by perchlorate administration. 18 F-DOPAMINE or 18 F-DOPA PET is in terms of sensitivity and specificity superior to the other two options; these can moreover be increased by prior carbidopa administration. 56, 57 Unfortunately, the latter is available only in a few highly specified centres and is thus currently not of use for routine clinical praxis. Although of low sensitivity, 111 In-octreotidescintigraphy may be useful in MIBG-negative, highly undifferentiated or hemorrhagic metastasis.
treatMent of pheochroMocytoMa
The goal is removal of the tumour. For effective blood pressure control and prevention of hypertensive crisis, a sufficiently long preoperative treatment (about 7 days) with alpha-blockers should be applied. The drug of choice is phenoxybenzamine, a non-specific and non-competitive irreversible alpha-blocker. The initial dose of 10 mg twice a day should be slowly increased (recommended increment: 10mg/die) under tight blood pressure measurement; usually a final dose of 1-2 mg/kg/die is necessary, given best in 3 doses. 58 The aim is to achieve normotension, which should be documented with a 24h blood monitoring before the surgical intervention. The typical side effects of an effective alpha-blockade include tachycardia, orthostatic hypotension, gastrointestinal disturbances and oedema of the nasal mucosa. The last phenoxybenzamine dose should be given the night before surgery. To counterbalance the orthostatic hypotension induced by the alpha-receptors blockade, salt and liquid consumption should be advised. Alternatively, selective alpha 1-receptor blockers can be given; however, the lower effect on catecholamine excess along with a lack of studies on this medication render it inferior compared to phenoxybenzamine. Other drugs such as calcium channel blockers and beta-blockers as well as combined alpha and beta-blockers may be used. 58 Calcium channel antagonists do not produce orthostatic hypotension and are thus very well tolerated in normotensive patients with paroxysmal hypertension. Beta-blockers are of interest in cases with tachycardia, but due to the potential hypertension caused by beta 2 receptor blockage, they should be administrated together with the alpha blockers.
Hypertensive crisis is managed with sodiumnitroprusside, urapidil or phentolamine. Intraoperative pressure elevations due to tumour manipulation can be well controlled by continuous sodiumnitroprusside infusions.
Benign Tumours
Surgical intervention should be performed only in specialized and experienced centres. Minimal invasive endoscopic surgery is the method of choice and should be considered as the gold standard. The procedure may be either laparoscopic or retroperineoscopic. [59] [60] [61] [62] Adrenal sparing surgery should be preferred to adrenalectomy, especially in hereditary cases where controlateral manifestations and frequent reintervention might occur. 63, 64 In the case of MEN2, the pheochromocytoma removal should precede the thyroid surgery. Extra-adrenal abdominal, thoracic and pelvic tumours may be removed via endoscopic procedure and, in the case of multifocal tumours, within one intervention. 62, 65 The catecholamine normalization should be documented after the operation. In the instance of bilateral adrenal surgery, even if adrenal sparing, an adrenal insufficiency should be excluded by an ACTH test.
Malignant Tumours
The treatment is not curative, its aim being to reduce the morbidity (symptoms) caused by catecholamine excess and tumour infiltration/compression. 66 Individual doses typically range from 3.7 to 7.4 GBq and will be repeatedly administered at intervals of several months. "High dose" MIBG therapy (270-700 MBq/kgKG, maximum 37 GBq) has been introduced by a San Francisco group, achieving 13% CR and 50% PR in 30 patients. 67 The following dose dependent side effects have been observed: severe thrombocytopenia and neutropenia, hypothyroidism, hypertension, ovarian failure, nausea, vomiting, secondary infections. Conventional chemotherapy includes cyclophosphamide, vincristine and dacarbacine ("CVD", Averbuch protocol) in 3 -6 cycles depending on response.
The effect of other nuclear medicine treatments ( 90 Yttrium-or 177 Lutetium-DOTA-TOC/-NOC or -TATE) as well as chemotherapeutic drugs (Sorafenib, Sunitinib and VEGF antagonists) is currently under investigation.
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Hereditary Cases
At the moment there is no treatment which could prevent the tumour formation. The necessity of surgical intervention on clinically silent tumours identified within clinical screening of mutation carriers is still unclear. The wait-and-scan policy can be considered in pediatric patients, especially for syndromes related to benign manifestations. Each case should be assessed individually, taking into consideration concomitant "at risk" factors such as pregnancy or patient's activity. Medical or nuclear treatment of hereditary cases does not differ from apparently sporadic cases.
folloW-up
After successful treatment, there is no recommendation for periodical follow-up for patients with apparently sporadic pheochromocytoma, without a germ-line mutation in one of the susceptibility genes.
Patients with a germ-line mutation (syndromic patients) as well as non-syndromic patients (in which no mutation has been found in the known susceptibility genes) but with specific features such as young age at presentation (<20), multiple tumours or family history for paraganglial tumours, should be monitored life-long for recurrence of the disease. In addition, syndromic patients should be clinically screened for other features associated with the specific syndrome (see above).
The screening should include both radiological imaging as well as biochemical tests. There is no universally accepted time interval in which the screening for pheochromocytoma recurrence is carried out. In our experience, for carriers of an SDHB mutation a yearly interval is recommended. The same interval is recommended for von Hippel-Lindau syndrome in which screening for tumours of the kidneys and the pancreas is to be included. Intervals of 2 to 3 years are probably sufficient for patients with mutations of the SDHC and SDHD gene.
Genotype specific recommendations within each syndrome are necessary for better management and counselling of the patients. Future discoveries in the genetics of these syndromes (e.g. modifier genes) will improve our approach and make it more specific for each case. 
